Cash flow statement (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Disclosure of cash flow statement [Abstract] |
|
| Schedule of Change in Operating Assets |
| | | | | | | | Change in financial assets held at amortised cost | | | | Change in financial assets at fair value through profit or loss | | | | Change in derivative financial instruments | | | | Change in other operating assets | | | | Change in operating assets | | | |
|
| Schedule of Change in Operating Liabilities |
| | | | | | | | Change in deposits from banks | | | | Change in customer deposits | | | | Change in repurchase agreements | | | | Change in financial liabilities at fair value through profit or loss | | | | Change in derivative financial instruments | | | | Change in debt securities in issue at amortised cost | | | | Change in insurance contracts1 | | | | Change in investment contract liabilities | | | | Change in other operating liabilities2 | | | | Change in operating liabilities | | | |
1Includes insurance contracts presented within disposal group liabilities. 2Includes a decrease of £235 million (2024: decrease of £371 million; 2023: increase of £315 million) in respect of lease liabilities. |
| Schedule of Non-Cash and Other Items |
| | | | | | | | Interest expense and hedging valuation adjustments on subordinated liabilities1 | | | | Accretion of discounts and amortisation of premiums and issue costs | | | | Revaluation of investment properties | | | | Net gain on sale of financial assets at fair value through other comprehensive income | | | | Share of post-tax results of associates and joint ventures | | | | Profit on derecognition of joint ventures and associates | | | | Loss/(profit) on disposal of tangible fixed assets | | | | Net credit in respect of defined benefit schemes | | | | Depreciation and amortisation | | | | Regulatory and legal provisions | | | | Other provision movements | | | | Allowance for loan losses | | | | Write-off of allowance for loan losses, net of recoveries | | | | Impairment credit on undrawn balances | | | | Impairment credit on financial assets at fair value through other comprehensive income | | | | Transactions in own shares | | | | Transfers to income statement from reserves | | | | Foreign exchange impact on balance sheet2 | | | | | | | | | | | | Contributions to defined benefit schemes | | | | Payments in respect of regulatory and legal provisions | | | | | | | | | | | | | | | |
1Interest expense on subordinated liabilities and hedging valuation adjustments on subordinated debt, previously presented separately, are reported in aggregate. 2When considering the movement on each line of the balance sheet, the impact of foreign exchange rate movements is removed in order to show the underlying cash impact. |
| Schedule of Acquisition of Group Undertakings and Businesses |
| | | | | | | | | | | | | | | | | | Cash and cash equivalents | | | | | | | | | | | | Intangible assets (excluding goodwill) | | | | | | | | | | | | | | | | | | | | | | | | Goodwill arising on acquisition | | | | | | | | | | | | | | | | | | Less cash and cash equivalents acquired | | | | | | Net cash (inflow)/outflow arising from acquisition of subsidiaries and businesses | | | | | | Acquisition of and additional investment in joint ventures | | | | | | Net cash (inflow)/outflow from acquisitions in the year | | | | | |
|
| Schedule of Analysis of Cash and Cash Equivalents as Shown in the Balance Sheet |
| | | | | | | | | | | | | | | | | | Cash and balances at central banks | | | | | | Less mandatory reserve deposits1 | | | | | | | | | | | | Loans and advances to banks and reverse repurchase agreements with banks | | | | | | Less amounts with a maturity of three months or more | | | | | | | | | | | | Total cash and cash equivalents2 | | | | | |
1Mandatory reserve deposits are held with local central banks in accordance with statutory requirements. Where these deposits are not held in demand accounts and are not available to finance the Group’s day-to-day operations they are excluded from cash and cash equivalents. 2Included within cash and cash equivalents at 31 December 2025 is £16 million (2024: £23 million; 2023: £31 million) of restricted cash and cash equivalents held within the Group’s long-term insurance and investments operations, which is not immediately available for use in the business. |